Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention

The american college of rheumatology 1990 criteria for the classification of fibromyalgia

1990 • 9,396 citations

Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty

1994 • 2,614 citations

A National Survey of Stress Reactions after the September 11, 2001, Terrorist Attacks

2001 • 1,689 citations

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1998 • 1,367 citations

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

1990 • 1,132 citations

Psychological Reactions to Terrorist Attacks

2002 • 1,129 citations

Trials to assess equivalence: the importance of rigorous methods

1996 • 1,022 citations

Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1988 • 992 citations

Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues

2000 • 862 citations

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization

2001 • 692 citations

Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina

1995 • 506 citations

Platelet Activation With Unfractionated Heparin at Therapeutic Concentrations and Comparisons With a Low-Molecular-Weight Heparin and With a Direct Thrombin Inhibitor

1998 • 388 citations

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1999 • 335 citations

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

2001 • 317 citations

Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence

1995 • 272 citations

Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy

1987 • 271 citations

Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention

2001 • 251 citations

Design and analysis of non‐inferiority mortality trials in oncology

2002 • 236 citations

Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.

1995 • 189 citations

Direct thrombin inhibitors in cardiovascular medicine.

1994 • 185 citations

Individual Correlates of Health Service Utilization and the Cost of Poor Adjustment to Chronic Illness

1990 • 179 citations

Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention

2001 • 160 citations

Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)

2002 • 159 citations

Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab

1999 • 159 citations

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization

1998 • 156 citations

Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction

2002 • 144 citations

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization11The names and institutions participating in these trials are provided in the appendices of references 1 to 3.

2002 • 142 citations

Statistical Methods for Comparison to Placebo in Active-Control Trials

2001 • 136 citations

Psychological stress and the fibrositis/fibromyalgia syndrome.

1990 • 133 citations

Equivalence and noninferiority trials

2000 • 90 citations

Heparin modulates integrin function in human platelets

2001 • 77 citations

Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.

1994 • 74 citations

abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile

2002 • 21 citations

Acute coronary syndromes: a focus on thrombin.

2002 • 18 citations

Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs. conventional fibrinolytic therapy for acute myocardial infarction. GUSTO V randomized trial

2003 • 7 citations